Previous close | 85.14 |
Open | 84.80 |
Bid | 85.44 x 800 |
Ask | 85.48 x 1200 |
Day's range | 84.53 - 85.74 |
52-week range | 65.07 - 86.29 |
Volume | |
Avg. volume | 1,477,851 |
Market cap | 19.071B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 21.81 |
EPS (TTM) | 3.93 |
Earnings date | 07 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 88.18 |
Incyte (INCY) could produce exceptional returns because of its solid growth attributes.
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.